FDA approves Codman implantable infusion pump for treatment of movement disorders

Wed, 08/08/2012 - 6:41pm
Mass Device

Johnson & Johnson neurological devices subsidiary Codman & Shurtleff enters the neuromodulation market with FDA approval for the Medstream programmable infusion system for treatment of movement disorders.

Medstream infusion pump

The FDA granted PMA supplemental approval to Codman & Shurtleff for the Medstream programmable infusion device, an implantable infusion pump and catheter used in treatment of movement disorders.

The Medstream system delivers continuous doses of an anti-spasm drug directly to he spinal canal to relieve spasticity, a disorder affecting more than 12 million people worldwide, which is often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury, according to the company.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.